Kite and Arcellx collaborate on CAR-modified T-cell therapy for multiple myeloma
The collaboration will leverage Kite’s experience in cell therapy manufacturing to co-develop and co-commercialise Arcellx’s lead candidate CART-ddBCMA,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
12 Dec 22
The collaboration will leverage Kite’s experience in cell therapy manufacturing to co-develop and co-commercialise Arcellx’s lead candidate CART-ddBCMA,…
07 Dec 22
The two companies will jointly discover and develop a novel papain-like protease (PLpro) inhibitor oral antiviral candidate against…
29 Nov 22
AstraZeneca will develop and market an oral therapy for the treatment of inflammatory and respiratory diseases with focus…
09 Nov 22
Sanofi will make upfront and target nomination fees totalling up to $21.5m for identifying, synthesising and advancing up…
20 Oct 22
Under the terms of the deal, Jazz will obtain exclusive rights to develop and commercialise zanidatamab worldwide, excluding…
18 Oct 22
MacroGenics will receive an upfront payment of $60m and is eligible to receive up to $1.7bn in potential…
13 Oct 22
Tavros will receive $17.5M in an upfront payment, and up to $430.5M in milestone payments for the initial…
28 Sep 22
The collaboration will deploy automation, large-scale genome engineering, and advanced machine learning and artificial intelligence (AI) algorithms for…
23 Sep 22
GSK will obtain exclusive rights to develop and market Tebipenem HBr worldwide, excluding Japan and certain other Asian…
09 Sep 22
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…